Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes

MLA

Ziding Feng, et al. “Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.” Journal of the National Comprehensive Cancer Network, vol. 20, May 2022, pp. 451–59. EBSCOhost, https://doi.org/10.6004/jnccn.2020.7798.

APA

Ziding Feng, Eva E Shrader, Lynn M. Matrisian, Joshua A. Roth, Suresh T. Chari, & Naomi R. M. Schwartz. (2022). Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. Journal of the National Comprehensive Cancer Network, 20, 451–459. https://doi.org/10.6004/jnccn.2020.7798

Chicago

Ziding Feng, Eva E Shrader, Lynn M. Matrisian, Joshua A. Roth, Suresh T. Chari, and Naomi R. M. Schwartz. 2022. “Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.” Journal of the National Comprehensive Cancer Network 20 (May): 451–59. doi:10.6004/jnccn.2020.7798.